Matthew A J Duncton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5271064/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Minisci reactions: Versatile CH-functionalizations for medicinal chemists. MedChemComm, 2011, 2, 1135.	3.4	489
2	Identification and characterization of novel TRPV4 modulators. Biochemical and Biophysical Research Communications, 2009, 389, 490-494.	2.1	201
3	TRPV4 Agonists and Antagonists. Current Topics in Medicinal Chemistry, 2011, 11, 2216-2226.	2.1	157
4	Preparation of Heteroaryloxetanes and Heteroarylazetidines by Use of a Minisci Reaction. Journal of Organic Chemistry, 2009, 74, 6354-6357.	3.2	89
5	Preparation of Aryloxetanes and Arylazetidines by Use of an Alkylâ^'Aryl Suzuki Coupling. Organic Letters, 2008, 10, 3259-3262.	4.6	73
6	Arylphthalazines: Identification of a new phthalazine chemotype as inhibitors of VEGFR kinase. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 4696-4698.	2.2	49
7	Orally Absorbed Derivatives of the \hat{l}^2 -Lactamase Inhibitor Avibactam. Design of Novel Prodrugs of Sulfate Containing Drugs. Journal of Medicinal Chemistry, 2018, 61, 10340-10344.	6.4	43
8	Arylphthalazines as potent, and orally bioavailable inhibitors of VEGFR-2. Bioorganic and Medicinal Chemistry, 2009, 17, 731-740.	3.0	34
9	Preparation of Substituted Pyrimido[4,5-b]-1,4-benzoxazepines, Thiazepines, and Diazepines via a Pictetâ°'Spengler Cyclization. Journal of Organic Chemistry, 2005, 70, 9629-9631.	3.2	32
10	Novel tricyclic azepine derivatives: Biological evaluation of pyrimido[4,5-b]-1,4-benzoxazepines, thiazepines, and diazepines as inhibitors of the epidermal growth factor receptor tyrosine kinase. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 5102-5106.	2.2	32
11	Arylphthalazines. Part 2: 1-(Isoquinolin-5-yl)-4-arylamino phthalazines as potent inhibitors of VEGF receptors I and II. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 1579-1581.	2.2	30
12	5-Benzyloxytryptamine as an antagonist of TRPM8. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 7076-7079.	2.2	26
13	Identification of orally-bioavailable antagonists of the TRPV4 ion-channel. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 4011-4015.	2.2	26
14	Fragment- and structure-based drug discovery for developing therapeutic agents targeting the DNA Damage Response. Progress in Biophysics and Molecular Biology, 2021, 163, 130-142.	2.9	21
15	Tetrazolone as an acid bioisostere: application to marketed drugs containing a carboxylic acid. Organic and Biomolecular Chemistry, 2016, 14, 9343-9347.	2.8	15
16	2-Amino-5-arylbenzoxazole derivatives as potent inhibitors of fatty acid amide hydrolase (FAAH). MedChemComm, 2012, 3, 611.	3.4	14
17	A singleâ€step preparation of thiazolo[5,4â€ <i>b</i>]pyridine―and thiazolo[5,4â€ <i>c</i>]pyridine derivatives from chloronitropyridines and thioamides, or thioureas. Journal of Heterocyclic Chemistry, 2009, 46, 1125-1131.	2.6	10
18	Toward Orally Absorbed Prodrugs of the Antibiotic Aztreonam. Design of Novel Prodrugs of Sulfate Containing Drugs. Part 2. ACS Medicinal Chemistry Letters, 2020, 11, 162-165.	2.8	9

#	Article	IF	CITATIONS
19	Mining biologically-active molecules for inhibitors of fatty acid amide hydrolase (FAAH): Identification of phenmedipham and amperozide as FAAH inhibitors. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 6793-6796.	2.2	8
20	Discovery of potent, non-carbonyl inhibitors of fatty acid amide hydrolase (FAAH). MedChemComm, 2012, 3, 1258.	3.4	6
21	Early Drug Discovery and Development of Novel Cancer Therapeutics Targeting DNA Polymerase Eta (POLH). Frontiers in Oncology, 2021, 11, 778925.	2.8	5
22	Enantioselective synthesis of an octahydroindolizine (indolizidine) alcohol using an enzymatic resolution. Organic and Biomolecular Chemistry, 2017, 15, 2953-2961.	2.8	4
23	A Single-Step Synthesis of Azetidine-3-amines. Journal of Organic Chemistry, 2020, 85, 13317-13323.	3.2	4
24	Efficient Preparation of ((3â€Chloroâ€2â€fluoroâ€phenyl)â€[7â€methoxyâ€8â€(3â€morpholinâ€4â€ylâ€propoxy)â€10,11â€dihydroâ€5 for Inâ€Vivo Study. Synthetic Communications, 2006, 36, 347-354.	â €o xaâ€2	,4211â€triaz
25	Arylphthalazines: Identification of a New Phthalazine Chemotype as Inhibitors of VEGFR Kinase ChemInform, 2006, 37, no.	0.0	0